JianDao Health Files IPO Prospectus: Reaching 100,000 Users with Over 70% Software Accuracy, Reshaping Chronic Disease Management Through Digital Therapeutics

“The healthcare industry is a hard-core sector that tolerates no falsehoods,” said He Zeyi, founder of JIANDAO TECHNOLOGY. In her transition from scientist to entrepreneur, she has evolved from someone who identifies problems to someone who solves them.

One day in 2015, a clinical nutritionist who graduated from Columbia University and a longtime friend of He Zeyi requested a meeting. Getting straight to the point, the friend proposed developing a software application to help physicians and dietitians monitor and manage the health of patients with chronic metabolic diseases.

This dietitian specializes in clinical nutritional interventions and has conducted in-depth research on metabolic chronic diseases such as obesity, diabetes, and hypertension. She noted that while China has a large population affected by metabolic chronic diseases, there is still a lack of corresponding specialized treatment protocols, leading some patients to seek indiscriminate medical care in their urgency.

This is indeed the case. The Medium- and Long-Term Plan for the Prevention and Control of Chronic Diseases in China (2017–2025), issued by the General Office of the State Council on February 14, 2017, states that “chronic diseases are a category of illnesses that pose a serious threat to the health of Chinese residents and have become a major public health issue affecting the country’s economic and social development.”

With the economic development in China, rapid changes in nutrition and lifestyle have led to a surge in the prevalence of chronic metabolic diseases such as obesity, diabetes, fatty liver disease, and chronic kidney disease, with a noticeable trend toward younger patients. Diabetes has become the third major threat to human health, following cardiovascular and cerebrovascular diseases and malignant tumors.

According to data released by the International Diabetes Federation (IDF), the global number of diabetes patients aged 20–79 reached 387 million in 2014 and is projected to reach 592 million by 2035. The latest statistics indicate that among individuals with chronic metabolic diseases in China, the number of diabetes patients has reached as high as 98.4 million.

According to a survey by the World Health Organization, 60% of the causes of chronic diseases are attributed to individual lifestyle factors, 15% to genetic factors, and the remainder to medical conditions, social circumstances, climate, and other factors. Additionally, according to surveys by the U.S. Department of Agriculture, proper nutritional measures can significantly reduce the incidence and mortality rates of diseases, such as a 25% reduction in heart disease, a 20% reduction in respiratory infections, and up to a 50% reduction in diabetes.

Taking diabetes as an example, apart from the 15% of cases caused by genetic factors, the majority of diabetes cases can be successfully managed through lifestyle interventions such as dietary modifications, physical exercise, and adjustments to daily habits.

However, China has fewer than 4,000 registered dietitians. Medical resources are also severely insufficient, as physicians at large hospitals are overburdened while those at small clinics have limited capabilities. Consequently, patients with chronic diseases do not receive adequate dietary nutrition advice or detailed dietary monitoring. This leads to poor adherence across the patient population and a high rate of inaccurate information provided during medical consultations, ultimately resulting in inadequate control of chronic diseases.

He Zeyi stated, “JIANDAO TECHNOLOGY provides patients with solutions through digital means, including personalized management approaches and methods for improving lifestyle habits, dietary structure, and physical activity, to achieve effective disease and risk control.”

So, what is the connection between a software application and the treatment of chronic diseases?

This involves an innovative approach—Digital Therapeutics (DTx). As the largest industry alliance in the field of digital therapeutics, the Digital Therapeutics Alliance provides a clear definition of digital therapeutics in its report. Digital therapeutics are software-based interventions that deliver evidence-based therapeutic treatments to patients for the prevention, management, or treatment of diseases.

At the 2018 BIO International Convention, digital therapeutics were defined as software-based interventions that are clinically validated and FDA-approved, and have been demonstrated in randomized clinical trials to safely and effectively improve patient outcomes.

In September 2017, Pear Therapeutics’ ReSET was approved, becoming the first FDA-cleared prescription digital therapeutic for the treatment of substance use disorder (SUD).

Given the market gap and demand, JIANDAO TECHNOLOGY aims to become a leading player in China’s digital therapeutics sector. Benchmarking against Pear Therapeutics, JIANDAO TECHNOLOGY is dedicated to the integrated application of artificial intelligence, big data, nutrition science, and health management. It strives to build a healthcare information ecosystem spanning homes, communities, and hospitals, leveraging advanced technologies such as deep learning and cognitive computing to develop data-driven medical solutions.

In 2016, He Zeyi’s team launched a mobile application designed to assist patients with diabetes in self-managing their health. Specifically developed for diabetic patients who have undergone inpatient treatment, this product is provided to patients by healthcare institutions.

This product achieved remarkable results in a trial conducted at a UK hospital. Recognizing its significant potential for in-depth research, He Zeyi’s team decided to seize the momentum and leverage this project to explore broader possibilities in their careers.

In 2017, JIANDAO TECHNOLOGY was founded in Hangzhou, China.

JIANDAO TECHNOLOGY’s co-founding team boasts an impressive lineup. Chairman He Zeyi holds a Ph.D. in Data Science from the University of York (UK), served as a founding director of Wikipedia UK, and previously worked as a senior consultant at British Telecom, bringing extensive experience in the big data industry. Co-founder Kan Jing holds a Ph.D. in Artificial Intelligence from the University of York (UK) and completed postdoctoral research at Newcastle University Medical School. He is also the author of the English monograph *Functional Brain Imaging Methods Using Magnetoencephalography*.

It is understood that the core co-founding team of JIANDAO TECHNOLOGY includes PhDs in Clinical Medicine and Cardiovascular Medicine, as well as a team of experts specializing in nutrition and public nutrition education. He Zeyi stated frankly that JIANDAO TECHNOLOGY, composed of experts from various disciplines, boasts a highly comprehensive and diverse talent structure. In addition, JIANDAO TECHNOLOGY has a contracted advisory team consisting of both Chinese and international clinical experts.

Notably, the core team of JIANDAO TECHNOLOGY is distributed across three countries. In addition to Hangzhou, the company has branches in London, UK, and California, US. The three teams collaborate remotely, maintaining 24/7 communication to jointly carry out product research and development, technology transfer, and product launch trials. As of 2019, JIANDAO TECHNOLOGY held 15 software copyrights and 3 Chinese utility model patents. Among its 8 invention patents for scientific and technological innovations, two are UK invention patents.

The professional team has gained the favor of investment institutions. In early 2018, JIANDAO TECHNOLOGY completed its angel round of financing.

In 2018, JIANDAO TECHNOLOGY, having completed its financing round, did not immediately expand into the market. Instead, it focused on laying a solid foundation by establishing a comprehensive domestic video-based nutritional database for culinary dishes. This database contains tens of millions of images and includes evaluations and analyses of over 50,000 Chinese dishes and more than 20,000 raw ingredients, thereby laying the groundwork for subsequent adjustments to nutritional structures.

Why do patients fall ill? What is the severity of their conditions, and how can these be assessed? To achieve more precise results, JIANDAO TECHNOLOGY has developed multiple models, including a personal chronic disease risk assessment model, an individual metabolic and nutritional requirement model, and a dietary risk factor control model. Currently, patents are being filed for several of these models.

In 2019, JIANDAO TECHNOLOGY launched two innovative products: the Intelligent Health Checkup Assessment and Management System and the AI-Powered Family Doctor Assistant.

The Intelligent Health Examination Assessment and Management System leverages big data algorithms, expert knowledge graphs, and functional recognition patterns. It comprises automatically generated "1+X" health examination plans and lifestyle health assessment reports during the pre-examination phase, along with a post-examination data management middle platform for the examination center and a personalized management terminal for examinees. This system helps hospitals address user management challenges, deliver precise experiences, and enable intelligent post-examination management.

After patients obtain their physical examination reports, the software system poses targeted questions to assess their risk of chronic diseases, identifies pathogenic factors affecting health—such as unreasonable dietary structure or excessive intake of certain types of food—and provides recommendations for nutritional and lifestyle interventions.

Physicians issue health prescriptions via a WeChat mini-program, allowing patients to view their medical examination reports and improvement recommendations through the same platform. This system is suitable for hospitals, health check-up centers, and large state-owned enterprises, with its cumulative user base exceeding 100,000. He Zeyi stated that this system enables health check-up centers to manage nearly all aspects of out-of-hospital health management and monitoring.

On the other hand, JIANDAO TECHNOLOGY has leveraged technologies such as big data algorithms, expert knowledge graphs, and functional recognition patterns to develop an innovative product for family doctors—the Family Doctor Intelligent Assistant. Phrases like “signed up but hard to schedule appointments,” “signed up but no actual engagement,” “poor service quality with insufficient specialization in general practice,” and “overcrowded hospitals for both major and minor illnesses, making medical access difficult” highlight the significant dilemmas currently facing family doctors in community hospitals. While the state continues to increase policy support for primary healthcare infrastructure, community hospital family doctors still face concrete challenges such as a severe shortage of talent and disorganized, subpar services. These physicians require a broad foundation of knowledge across all medical specialties, effective community patient management strategies, and extensive clinical experience. Burdened by heavy workloads and expected to be generalists rather than specialists, family doctors are overwhelmed.

This product consists of two components. The “Personal Health Assessment and Intervention System,” based on the “UK General Practitioner Guidelines,” effectively empowers family doctors and community health centers through features such as fully automated data transmission management, intelligent data middle-platform assessment, and one-click generation of intervention plans. After users sign up with their family doctors via the “Family Doctor Intelligent Assistant—Doctor’s End,” they establish personal basic health data profiles (including personal physical examination results and lifestyle habits). Leveraging JIANDAO TECHNOLOGY’s Personal Health Assessment and Intervention System, the platform generates a “Personal Disease Risk Assessment Report,” a “Personalized Health Management Plan,” and a patient follow-up plan.

Users can adjust their dietary structure and eating habits, and implement nutritional and lifestyle interventions based on health management recommendations provided by the “Smart Assistant” on their mobile devices. This helps reduce disease risk, improve physical fitness, and cultivate healthy lifestyle habits. Family doctors are liberated from previously cumbersome administrative tasks, enabling them to manage a larger resident population in an organized and efficient manner through the “Family Doctor Smart Assistant.” This enhances their service quality and aligns with the national policy shift from “treating diseases” to “preventive care.”

Furthermore, JIANDAO TECHNOLOGY is developing intelligent robotic products tailored for patients with gestational diabetes. In He Zeyi’s view, technology serves as a supplement to human labor; artificial intelligence cannot replace physicians, clinical dietitians, or health managers. The business model of JIANDAO TECHNOLOGY is to provide services to medical institutions.

He Zeyi stated that JIANDAO TECHNOLOGY will focus on market expansion in the coming period, striving to surpass one million system users. Looking ahead, the company hopes its system will be approved by the National Medical Products Administration (NMPA) for application in clinical management and lifestyle intervention. Institutions interested in the company should contact the financing assistant, Xiao Yun: DongMai_Investent